Roundup settlement expected before Christmas, Bayer CEO says

By Reuters News

- German drugs and agrochemicals group Bayer BAYGn.DE is expecting a $7.25 billion settlement on its Roundup weedkiller to come before Christmas, CEO Bill Anderson said on Tuesday.

The company is seeking to resolve tens of thousands of Roundup lawsuits through the proposed settlement, which is under review by a Missouri state court judge in St. Louis.

  • "It could be any week now," Anderson said in a press call following the company's results, adding there would be a much smaller number of individual cases after the settlement.

  • Bayer is facing approximately 65,000 claims in US state and federal courts from plaintiffs who say they ​developed non-Hodgkin lymphoma and other forms of cancer after using Roundup ​at home or on the job.

  • Following a Supreme Court victory in June, Bayer moved its US Roundup business into a unit dubbed Ruveon and internally separated it from the rest of the organisation.

  • Bayer has said that decades of studies have shown glyphosate, Roundup's active ingredient, is safe and does not cause cancer.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.